Screening for prostate cancer: the current evidence and guidelines controversy
about
Current status of biomarkers for prostate cancerMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerCirculating tumor DNA: a promising biomarker in the liquid biopsy of cancerUpdate on age-appropriate preventive measures and screening for Canadian primary care providersNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesCell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristicsPatient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study.Screening for prostate cancer: the debate continuesMicroRNA binding site polymorphisms as biomarkers in cancer management and research.Screening for disease, psychological testing, and psychotherapy Looking behind the mirror.Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.Prostate Cancer Screening Among American Indians and Alaska Natives: The Health and Retirement Survey, 1996-2008.Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer preventionCommunication about colorectal cancer screening in Britain: public preferences for an expert recommendation.Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human CancersGeneralized principles of stochasticity can be used to control dynamic heterogeneityConceptualizing a tool to optimize therapy based on dynamic heterogeneity.Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancerGenetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men.Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers.Frequency-selective electrokinetic enrichment of biomolecules in physiological media based on electrical double-layer polarization.Patient-Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey.Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.Serum protein electrophoresis in the evaluation of lytic bone lesionsMise à jour sur la prévention et le dépistage selon l’âge à l’intention des médecins de soins primaires canadiens.Profile of common prostate cancer risk variants in an unscreened Romanian population.The Clinical Efficacy of Prostate Cancer Screening in Worldwide and Iran: Narrative Review.Contrast enhanced transrectal ultrasound for the detection of prostate cancer: a randomized, double-blind trial of dutasteride pretreatment.Exploring factors that might influence primary-care provider discussion of and recommendation for prostate and colon cancer screening.
P2860
Q24600574-F03B26D2-1224-4A6A-9329-18237C59C1F6Q26739708-65BED3E1-C608-426C-84C3-08904422B26DQ26746010-9B450372-2141-4BDA-B4FC-478BDD7458B1Q26765382-60886A32-5570-4C80-A84A-2D43038DB001Q26825644-C88F8F1E-589C-4A0B-8FB1-C691AB8A5F69Q26865810-6262CEED-A1DC-40CC-B971-F6CBEFA04508Q28482384-2752D2D6-452C-45CF-A76C-51E7A7F5F90BQ30543371-3970BAF3-9BA7-49B7-BFB7-3486DC0C9C4EQ33885776-0FE87494-96B2-41AC-A4A7-3F5ECF098596Q34019040-92BD1A44-CA3F-41ED-AFD3-E78AC608095AQ34653876-F1FDA677-6A9C-422E-A873-3366AEBA0E75Q35178504-4C62490F-192E-4576-B2D0-56E848F18B61Q36003236-0CFC29D3-E7D0-47BB-8255-E28A3EEBC068Q36080332-C054E2A2-8F3A-4BDC-B430-C7BFA570632FQ36451775-67D001B1-A00B-4BB0-B4DB-5BA9FACC2ECCQ36657311-E57ABCDC-F804-4FB2-BE2F-67931EFE831FQ36745875-3547F5EC-0878-4C1F-864D-607EBBF7FD9CQ36745877-E9C9F7FA-CA9D-444A-9E5C-F4C71426DFAAQ37055427-113E5035-8AE4-4324-A2CD-5841E08F90F5Q37398384-66D59885-3B03-447D-B5A3-68F86FA4971BQ37610431-7A1A3B43-FBC6-420E-BD40-2F2723ED0017Q40094770-5218AD76-1156-4606-A88C-7192ACC37401Q40266746-CFBDA78F-9C71-4239-B036-69553C7BCE65Q40395964-3367886C-58D4-4690-8A29-6702D9D9FB07Q41983339-2F157CD7-F5F4-48B1-A440-0EF9DC369F2FQ45942216-B3BC9817-0989-4DBB-82E4-94AAE45882D6Q47228640-2FB6A927-4A26-4B39-8387-6FD160D1C878Q51734241-84ADE6B6-CBF5-4C3C-A61C-A0BB7FCC6A30Q55103167-A54A2CD6-37BB-45EA-9035-6B3ACD910AF8Q55194676-8D421589-4A6B-4EF6-86AE-4DB7C8FC804A
P2860
Screening for prostate cancer: the current evidence and guidelines controversy
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Screening for prostate cancer: the current evidence and guidelines controversy
@ast
Screening for prostate cancer: the current evidence and guidelines controversy
@en
Screening for prostate cancer: the current evidence and guidelines controversy
@nl
type
label
Screening for prostate cancer: the current evidence and guidelines controversy
@ast
Screening for prostate cancer: the current evidence and guidelines controversy
@en
Screening for prostate cancer: the current evidence and guidelines controversy
@nl
prefLabel
Screening for prostate cancer: the current evidence and guidelines controversy
@ast
Screening for prostate cancer: the current evidence and guidelines controversy
@en
Screening for prostate cancer: the current evidence and guidelines controversy
@nl
P2093
P3181
P1476
Screening for prostate cancer: the current evidence and guidelines controversy
@en
P2093
Gomella LG
Showalter T
Trabulsi EJ
P304
P3181
P407
P577
2011-10-01T00:00:00Z